135 related articles for article (PubMed ID: 37835568)
1. Diagnostics and Therapeutics in Early Stage Breast Cancer Receiving Neoadjuvant Systemic Therapy.
Belli P; Palma S; Costantini M
Cancers (Basel); 2023 Oct; 15(19):. PubMed ID: 37835568
[TBL] [Abstract][Full Text] [Related]
2. Advances in neoadjuvant therapy for HER2-positive breast cancers: a narrative review.
Wang Q; Wang X; Yang Y
Gland Surg; 2022 Aug; 11(8):1415-1423. PubMed ID: 36082097
[TBL] [Abstract][Full Text] [Related]
3. Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy.
Chien AJ; Chambers J; Mcauley F; Kaplan T; Letourneau J; Hwang J; Kim MO; Melisko ME; Rugo HS; Esserman LJ; Rosen MP
Breast Cancer Res Treat; 2017 Aug; 165(1):151-159. PubMed ID: 28503722
[TBL] [Abstract][Full Text] [Related]
4. Variation in use of neoadjuvant chemotherapy in patients with stage III breast cancer: Results of the Dutch national breast cancer audit.
Spronk PER; van Bommel ACM; Siesling S; Wouters MWJM; Vrancken Peeters MTFD; Smorenburg CH
Breast; 2017 Dec; 36():34-38. PubMed ID: 28942098
[TBL] [Abstract][Full Text] [Related]
5. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
6. [Role of clustered HER2/neu amplification as a marker for a special sensitivity to neoadjuvant anti-HER2 therapy with trastuzumab in patients with stage II-III breast cancer].
Kolyadina IV; Zavalishina LE; Ganshina IP; Andreeva YY; Frank GA; Gordeeva OO; Zhukova LG; Meshcheryakov AA; Savelov NA; Tuzova EA; Morozov DA; Poddubnaya IV
Arkh Patol; 2019; 81(6):56-62. PubMed ID: 31851193
[TBL] [Abstract][Full Text] [Related]
7. Deep learning radiomics of ultrasonography can predict response to neoadjuvant chemotherapy in breast cancer at an early stage of treatment: a prospective study.
Gu J; Tong T; He C; Xu M; Yang X; Tian J; Jiang T; Wang K
Eur Radiol; 2022 Mar; 32(3):2099-2109. PubMed ID: 34654965
[TBL] [Abstract][Full Text] [Related]
8. Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer.
de Melo Gagliato D; Lei X; Giordano SH; Valero V; Barcenas CH; Hortobagyi GN; Chavez-MacGregor M
Oncologist; 2020 Sep; 25(9):749-757. PubMed ID: 32431013
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Therapy for Early-Stage Breast Cancer: Current Practice, Controversies, and Future Directions.
Santa-Maria CA; Camp M; Cimino-Mathews A; Harvey S; Wright J; Stearns V
Oncology (Williston Park); 2015 Nov; 29(11):828-38. PubMed ID: 26573062
[TBL] [Abstract][Full Text] [Related]
10. Complete Metabolic Response on Interim
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
[TBL] [Abstract][Full Text] [Related]
11. The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data.
Borges A; Pereira F; Redondo P; Antunes L; Vieira C; Antunes P; Bento MJ; Sousa S; Lopes JM; Rocha-Gonçalves F; de Sousa JA; Pereira DS; Borges M
Health Econ Rev; 2021 Sep; 11(1):33. PubMed ID: 34505956
[TBL] [Abstract][Full Text] [Related]
12. Development, verification, and comparison of a risk stratification model integrating residual cancer burden to predict individual prognosis in early-stage breast cancer treated with neoadjuvant therapy.
Hou N; Wu J; Xiao J; Wang Z; Song Z; Ke Z; Wang R; Wei M; Xu M; Wei J; Qian X; Xu X; Yi J; Wang T; Zhang J; Li N; Fan J; Hou G; Wang Y; Wang Z; Ling R
ESMO Open; 2021 Oct; 6(5):100269. PubMed ID: 34537675
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial.
Hurvitz SA; Martin M; Symmans WF; Jung KH; Huang CS; Thompson AM; Harbeck N; Valero V; Stroyakovskiy D; Wildiers H; Campone M; Boileau JF; Beckmann MW; Afenjar K; Fresco R; Helms HJ; Xu J; Lin YG; Sparano J; Slamon D
Lancet Oncol; 2018 Jan; 19(1):115-126. PubMed ID: 29175149
[TBL] [Abstract][Full Text] [Related]
14. Factors Predicting Response in Breast Cancer Receiving Neoadjuvant Therapy and the Role of Ki67 Labeling Index.
Ekinci F; Uzun M; Demir B; Unek IT; Erdogan AP
J Coll Physicians Surg Pak; 2023 Aug; 33(8):872-878. PubMed ID: 37553925
[TBL] [Abstract][Full Text] [Related]
15. Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available evidence and clinical implications.
Griguolo G; Bottosso M; Vernaci G; Miglietta F; Dieci MV; Guarneri V
Cancer Treat Rev; 2022 Jan; 102():102323. PubMed ID: 34896969
[TBL] [Abstract][Full Text] [Related]
16. Real-world treatment patterns and effectiveness outcomes in patients with early-stage triple-negative breast cancer.
Haiderali A; Rhodes WC; Gautam S; Huang M; Sieluk J; Skinner KE; Schwartzberg LS
Future Oncol; 2021 Oct; 17(29):3819-3831. PubMed ID: 34227400
[TBL] [Abstract][Full Text] [Related]
17. Use of Trastuzumab for Neoadjuvant Therapy of HER2+ Breast Cancer - 5-Years of Experience in a Single Clinic.
Zuazana B; Luboš P; Renata C
Klin Onkol; 2018; 31(3):191-199. PubMed ID: 30441972
[TBL] [Abstract][Full Text] [Related]
18. Trends in neoadjuvant chemotherapy versus surgery-first in stage I HER2-positive breast cancer patients in the National Cancer DataBase (NCDB).
Zeidman M; Schmidt H; Alberty-Oller JJ; Pisapati KV; Ahn S; Mazumdar M; Ru M; Moshier E; Port E
Breast Cancer Res Treat; 2021 May; 187(1):177-185. PubMed ID: 33392839
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.
Zhou M; Wang S; Wan N; Yuan S; Hu X; Zhou W; Qing B; Liu M; Sun W; Fan P; Wang J; Cao H; Xu H; Dai B; Tang P; Qian L; Zhao X; Xiao J; Zhou H; Hu J; Ding L; Tripodi D; Zdenkowski N; O'Keefe TJ; Sanchez AM; Chen L; Zhang P; Xu F
Ann Transl Med; 2022 Dec; 10(24):1387. PubMed ID: 36660637
[TBL] [Abstract][Full Text] [Related]
20. Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.
Tung NM; Boughey JC; Pierce LJ; Robson ME; Bedrosian I; Dietz JR; Dragun A; Gelpi JB; Hofstatter EW; Isaacs CJ; Jatoi I; Kennedy E; Litton JK; Mayr NA; Qamar RD; Trombetta MG; Harvey BE; Somerfield MR; Zakalik D
J Clin Oncol; 2020 Jun; 38(18):2080-2106. PubMed ID: 32243226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
